The Europe GMP cytokines market is expected to reach US$ 43.35 million by 2027 from US$ 23.84 million in 2019; it is estimated to grow at a CAGR of 7.8% from 2020 to 2027.
The growth of the Europe GMP cytokines market is attributed to key driving factors, such as increase in acceptance of cytokines for cancer and autoimmune therapies and potential contribution in stem cell therapy. However, high cost associated with GMP cytokines therapy is expected to obstruct the growth of the market to a certain extent during the forecast period.
Cytokines play a significant role in regulating innate and adaptive immunity, which enables cells of the immune system to communicate over short distances. The cytokines therapy to activate cancer patients' immune systems has been an essential parameter in the treatment. Several research activities have proved cytokines' ability to limit tumor cell growth by a direct anti-proliferative or pro-apoptotic activity. Moreover, some cytokines indirectly inhibit tumor growth by stimulating the cytotoxic activity of immune cells against tumor cells. Similarly, rising prevalence of autoimmune disorders is expected to impact the adoption of cytokines-based therapeutics positively. According to data published by NHS in 2018, in the UK, more than 10 million people suffered from arthritis. This effectiveness of cytokines therapies over cancer and autoimmune disorders, coupled with increasing prevalence of the disease, is likely to drive the market by 2027. Additionally, increasing number of investments and collaborations by market players to develop cytokines therapies over chronic disorders are also expected to accelerate the market growth.
Europe has been witnessing a growing number of COVID-19 cases since its outbreak. Cytokines play a significant role in the immune reaction to coronavirus infection. Some of the market players are also focusing on developing cytokine-based therapies to deal with COVID-19 pandemic. This factor is expected to positively impact the Europe GMP cytokines market during the forecast period.
Based on type, the Europe GMP cytokines market is segmented into TNF, interleukins, growth factors, and others. The growth factors segment held the largest share of the market in 2019, whereas, the TNF segment is expected to register the highest CAGR in the market during the forecast period.
In terms of application, the Europe GMP cytokines market, is segmented into cell and gene therapy, tissue-engineered products, and others. The cell and gene therapy segment held the largest share of the market in 2019; however, the tissue-engineered products segment is anticipated to register the highest CAGR in the market during the forecast period.
A few of the primary and secondary sources associated with this report on the Europe GMP cytokines market are Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), International Stem Cell Corporation, (ISCO) and Asociación Española Contra el Cáncer (AECC).